2025
A Vaccine to Block Plasmodium falciparum Transmission.
Healy S, Sagara I, Assadou M, Katile A, Kone M, Imeru A, Kwan J, Swihart B, Fintzi J, Potter G, Zeguimé A, Dolo A, Diarra B, Narum D, Rausch K, MacDonald N, Zhu D, Mohan R, Thera I, Morrison R, Zaidi I, Doritchamou J, Sylla D, Hume J, Coulibaly M, Morelle D, Lievens M, Doumbo O, Duffy P. A Vaccine to Block Plasmodium falciparum Transmission. NEJM Evidence 2025, 4: evidoa2400188. PMID: 40552966, DOI: 10.1056/evidoa2400188.Peer-Reviewed Original ResearchConceptsStandard membrane feeding assayPfs230D1-EPASafety trialsAntibody responseEnd pointsSkin feeding assaysTransmission-reducing activityWeeks of follow-upMembrane feeding assaysAs-treated populationPrimary efficacy analysisSecondary end pointsPrimary end pointInfected mosquitoesEnzyme-linked immunosorbent assayMalian adultsMalaria vaccineComparator-controlledDouble-blindProportion of infected mosquitoesDosing regimensEfficacy analysisThird doseYears postvaccinationBlock disease transmissionTransarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim J, Zhao H, Li C, Madoff D, Ghobrial R, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry A, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel A, Finn R, Llovet J, investigators L. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet 2025, 405: 203-215. PMID: 39798578, DOI: 10.1016/s0140-6736(24)02575-3.Peer-Reviewed Original ResearchConceptsEastern Cooperative Oncology GroupNon-metastatic hepatocellular carcinomaProgression-free survivalTreatment-related adverse eventsPembrolizumab groupPhase 3 studyTransarterial chemoembolisationPlacebo groupHepatocellular carcinomaIntention-to-treatOverall survivalDouble-blindPerformance statusAdverse eventsFollow-upEastern Cooperative Oncology Group performance statusChild-Pugh class A diseaseMedian progression-free survivalSolid Tumors version 1.1Blinded independent central reviewA-fetoprotein levelAlbumin-bilirubin gradeResponse Evaluation CriteriaAs-treated populationMedian follow-up
2023
Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial
Pittet L, Moore C, McDonald E, Barry S, Bonten M, Campbell J, Croda J, Dalcolmo M, Davidson A, Douglas M, Gardiner K, Gwee A, Jardim B, Lacerda M, Lucas M, Lynn D, Manning L, de Oliveira R, Perrett K, Prat-Aymerich C, Richmond P, Rocha J, Rodriguez-Baño J, Warris A, Wood N, Messina N, Curtis N, Curtis N, Davidson A, Gardiner K, Gwee A, Jamieson T, Messina N, Morawakage T, Perlen S, Perrett K, Pittet L, Sastry A, Teo J, Orsini F, Lee K, Moore C, Vidmar S, Pittet L, Ali R, Dunn R, Edler P, Gell G, Goodall C, Hall R, Krastev A, La N, McDonald E, McPhate N, Nguyen T, Ren J, Stevens L, Messina N, Alamrousi A, Bonnici R, Dang T, Germano S, Hua J, McElroy R, Razmovska M, Reddiex S, Wang X, Anderson J, Azzopardi K, Bennett-Wood V, Czajko A, Mazarakis N, McCafferty C, Oppedisano F, Ortika B, Pell C, Spry L, Toh R, Velagapudi S, Vlahos A, Wee-Hee A, Ramos P, De La Cruz K, Gamage D, Karunanayake A, Mezzetti I, Ong B, Singh R, Sooriyarachchi E, Nicholson S, Cain N, Brizuela R, Huang H, Abruzzo V, Bealing M, Bimboese P, Bowes K, Burrell E, Chan J, Cushnahan J, Elborough H, Elkington O, Fahey K, Fernandez M, Flynn C, Fowler S, Andrit M, Gladanac B, Hammond C, Ma N, Macalister S, Milojevic E, Mojeed J, Nguyen J, O'Donnell L, Olivier N, Ooi I, Reynolds S, Shen L, Sherry B, Spotswood J, Wedderburn J, Younes A, Legge D, Bell J, Cheah J, Cobbledick A, Lim K, Elia S, Addlem L, Bourke A, Brophy C, Henare N, Jenkins N, Machingaifa F, Miller S, Mitchell K, Pitkin S, Wall K, Villanueva P, Crawford N, Pittet L, Norton W, Tan N, Chengodu T, Dawson D, Gordon V, Korman T, O'Bryan J, Abruzzo V, Agius S, Bannister S, Bucholc J, Burns A, Camesella B, Carlin J, Ciaverella M, Curtis M, Firth S, Guo C, Hannan M, Hill E, Joshi S, Lieschke K, Mathers M, Odoi S, Rak A, Richards C, Steve L, Stewart C, Sudbury E, Thomson H, Watts E, Williams F, Young A, Glenn P, Kaynes A, De Floy A, Buchanan S, Sondag T, Xie I, Edmund H, Byrne B, Keeble T, Ngien B, Noonan F, Wearing-Smith M, Clarke A, Davies P, Eastwood O, Ellinghaus A, Ghieh R, Hilton Z, Jennings E, Kakkos A, Liang I, Nicol K, O'Callaghan S, Osman H, Rajaram G, Ratcliffe S, Rayner V, Salmon A, Scheppokat A, Stevens A, Street R, Toogood N, Wood N, Bahaduri T, Baulman T, Byrne J, Carter C, Corbett M, Dao A, Desylva M, Dunn A, Gardiner E, Joyce R, Kandasamy R, Munns C, Pelayo L, Sharma K, Sterling K, Uren C, Colaco C, Douglas M, Hamilton K, Bartlett A, McMullan B, Palasanthiran P, Williams P, Beardsley J, Bergant N, Lagunday R, Overton K, Post J, Al-Hindawi Y, Barney S, Byrne A, Mead L, Plit M, Lynn D, Benson S, Blake S, Botten R, Chern T, Eden G, Griffith L, James J, Lynn M, Markow A, Sacca D, Stevens N, Wesselingh S, Doran C, Barry S, Sawka A, Evans S, Goodchild L, Heath C, Krieg M, Marshall H, McMillan M, Walker M, Richmond P, Amenyogbe N, Anthony C, Arnold A, Arrowsmith B, Ben-Othman R, Clark S, Dunnill J, Eiffler N, Ewe K, Finucane C, Flynn L, Gibson C, Hartnell L, Hollams E, Hutton H, Jarvis L, Jones J, Jones J, Jones K, Kent J, Kollmann T, Lalich D, Lee W, Lim R, McAlister S, McDonald F, Meehan A, Minhaj A, Montgomery L, O'Donnell M, Ong J, Ong J, Parkin K, Perez G, Power C, Rezazadeh S, Richmond H, Rogers S, Schultz N, Shave M, Skut P, Stiglmayer L, Truelove A, Wadia U, Wallace R, Waring J, England M, Latkovic E, Manning L, Herrmann S, Lucas M, Lacerda M, Andrade P, Barbosa F, Barros D, Brasil L, Capella A, Castro R, Costa E, de Souza D, Dias M, Dias J, Ferreira K, Figueiredo P, Freitas T, Furtado A, Gama L, Godinho V, Gouy C, Hinojosa D, Jardim B, Jardim T, Junior J, Lima A, Maia B, Marins A, Mazurega K, Medeiros T, Melo R, Moraes M, Nascimento E, Neves J, Oliveira M, Oliveira T, Oliveira I, Otsuka A, Paes R, Pereira H, Pereira G, Prado C, Queiroz E, Rodrigues L, Rodrigues B, Sampaio V, Santos A, Santos D, Santos T, Santos E, Sartim A, Silva A, Silva J, Silva E, Simão M, Soares C, Sousa A, Trindade A, Val F, Vasconcelos A, Vasconcelos H, Croda J, Abreu C, Almeida K, de Andrade C, Angelo J, de Araújo Arcanjo G, Arruda B, Ayala W, Barbosa A, Batista F, de Morais Batista F, de Jesus Costa M, Croda M, da Cruz L, Diogo R, Escobar R, Fernandes I, Figueiredo L, Gonçalves L, Lahdo S, dos Santos Lencina J, de Lima G, Matos L, Meireles B, Moreira D, Muranaka L, de Oliveira A, de Oliveira K, de Oliveira M, de Oliveira R, dos Reis Pereira A, Puga M, Ramos C, da Rosa T, dos Santos K, dos Santos C, dos Santos D, Santos K, da Silva P, da Silva P, dos Santos Silva D, da Silva P, da Rosa Soares B, Sperotto M, Tadokoro M, Tsuha D, Vieira H, Dalcolmo M, da Paixão C, Castro G, Collopy S, da Costa Silva R, da Silveira S, Da-Cruz A, de Carvalho A, de Cássia Batista R, De Freitas M, de Oliveira Ferreira A, de Souza A, Doblas P, dos Santos A, dos Santos V, dos Santos Gomes D, Fortunato A, Gomes-Silva A, Gonçalves M, Meireless P, da Costa Carvalho E, do Couto Motta F, de Mendonça L, dos Santos Pandine G, Pereira R, Maia I, da Rocha J, Romano J, dos Santos G, da Silva E, de Siqueira M, Soares Á, Bonten M, Arroyo S, Besten H, Boon A, Brakke K, Janssen A, Koopmans M, Lemmens T, Leurink T, Prat-Aymerich C, Septer-Bijleveld E, Stadhouders K, Troeman D, van der Waal M, van Opdorp M, van Sluis N, Wolters B, Kluytmans J, Romme J, van den Bijllaardt W, van Mook L, van Rijen M, Filius P, Gisolf J, Greven F, Huijbens D, Hassing R, Pon R, Preijers L, van Leusen J, Verheij H, Boersma W, Brans E, Kloeg P, Molenaar-Groot K, Nguyen N, Paternotte N, Rol A, Stooper L, Dijkstra H, Eggenhuizen E, Huijs L, Moorlag S, Netea M, Pranger E, Taks E, Oever J, Heine R, Blauwendraat K, Meek B, Erkaya I, Harbech H, Roescher N, Peeters R, Riele M, Zhou C, Calbo E, Marti C, Palomares E, Porcuna T, Barriocanal A, Barriocanal A, Casas I, Dominguez J, Esteve M, Lacoma A, Latorre I, Molina G, Molina B, Rosell A, Vidal S, Barrera L, Bustos N, Calderón I, Campos D, Carretero J, Castellano A, Compagnone R, de Arellano E, de la Serna A, del Toro Lopez M, Espindola M, Gutierrez A, Hernandez A, Jiménez V, Moreno E, Navarrete N, Paño T, Rodríguez-Baño J, Tristán E, Villegas M, Garces A, Amo E, Guerrero R, Goikoetxea J, Jorge L, Perez C, Álvarez M, Cuadra M, de las Revillas Almajano F, Garcia P, Poderos T, Rico C, Sanchez B, Valero O, Vega N, Campbell J, Barnes A, Catterick H, Cranston T, Dawe P, Fletcher E, Fouracre L, Gifford A, Kirkwood J, Martin C, McAnew A, Mitchell M, Newman G, O'Connell A, Onysk J, Quinn L, Rhodes S, Stone S, Symons L, Tripp H, Warris A, Watkins D, Whale B, Harding A, Lockhart G, Sidaway-Lee K, Campbell J, Hilton S, Manton S, Webber-Rookes D, Winder R, Moore J, Bateman F, Gibbons M, Knight B, Moss J, Statton S, Studham J, Hall L, Moyle W, Venton T. Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial. EClinicalMedicine 2023, 64: 102203. PMID: 37719417, PMCID: PMC10500555, DOI: 10.1016/j.eclinm.2023.102203.Peer-Reviewed Original ResearchBacille Calmette-GuerinRecurrent herpes labialisHerpes simplex virusBCG-DenmarkHerpes labialisCold soresRandomised controlled trialsRecurrence of herpes simplex virusDose of study drugEffects of Bacille Calmette-GuerinControlled trialsAs-treated populationBacillus Calmette-Guerin vaccineRecurrent cold soresControl groupBurden of recurrenceMean survival timeIntention-to-treatNested randomised controlled trialImpact quality-of-lifeStudy drugLive attenuated vaccinesIntradermal doseOrofacial regionProportion of participants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply